# **Utilizing Transformer Models for Copy Number Variant (CNV) Calling**

# **Objective**

The primary objective of this project is to develop an advanced computational tool based on transformer models to accurately classify genomic sites for CNV analysis. This tool aims to address current limitations in CNV detection by leveraging the powerful capabilities of transformer models, known for their effectiveness in handling complex patterns in large-scale data.

### **Background and Significance**

CNVs contribute significantly to genetic diversity and have been implicated in various diseases, including cancer, neurodevelopmental disorders, and autoimmune diseases. Traditional methods for CNV detection, such as array comparative genomic hybridization (aCGH) and quantitative PCR (qPCR), have limitations in terms of resolution, scalability, and the ability to handle complex genomic data. The proposed transformer-based tool aims to overcome these limitations, providing a more robust and comprehensive approach to CNV analysis.

## **Data Acquisition and Preprocessing**

The project will harness data from the Human Pangenome Reference Consortium (HPRC), a rich resource of genomic information. This choice ensures access to a diverse and comprehensive range of human genomic sequences. Depending on model complexity, features such as coverage and other features like clipping read signatures and allele frequency (AAF) will be incorporated. Critical preprocessing steps such as normalization and scaling will be implemented. This is essential to ensure that the coverage data, which is inherently variable across different genomic regions, is standardized, making it more suitable for analysis by the transformer model.

# **Transformer Model Development**

Initial Structure: The project will commence with a simple transformer architecture, prioritizing the encoder mechanism to adeptly capture the sequential dependencies intrinsic to genomic sequences.

Optimization: The architecture, including aspects such as the number of layers, heads, and model dimensions, will be iteratively refined. This process aims to tailor the model specifically for the nuances of CNV detection.

Model Complexity: A key focus will be to monitor and mitigate overfitting, particularly given the high correlation between coverage data and predicted CNVs. Techniques such as dropout, regularization, and early stopping will be employed as necessary.

## **Training and Validation**

#### Training Approach

Labeled Dataset: The model will be trained on datasets labeled using hmcnc, an HMM-based CN caller. This approach ensures that the training data is of high quality and accurately reflects CNV occurrences.

#### Validation Strategy

Separate Dataset Evaluation: A rigorous validation process will be implemented, employing separate datasets to impartially evaluate the model's accuracy and reliability. This step is critical to ensure the model's efficacy in real-world scenarios.

#### Hyperparameter Tuning

Optimization Techniques: To fine-tune the model's hyperparameters for optimal performance, advanced techniques such as grid search or Bayesian optimization will be employed. This step is vital to enhance the model's efficiency and accuracy.

### **Advancing Personalized Healthcare**

Precision Medicine Tool: The successful development of this transformer model will mark a significant advancement in personalized medicine. By providing accurate and detailed CNV profiles, the tool will enable clinicians to understand individual genetic variations more profoundly.

Tailored Treatment Strategies: This understanding is pivotal in designing personalized treatment plans, particularly in areas such as oncology, where CNV profiles can significantly influence treatment response.

Preventive Healthcare: In the broader scope of healthcare, this tool can also contribute to preventive strategies by identifying genetic predispositions to various conditions, enabling early intervention.